臨床検査マッチングソフトウェアの市場規模、シェア、動向分析レポート：展開モード別、最終用途別、地域別、セグメント予測、2025年～2030年

臨床検査マッチングソフトウェア市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の臨床検査マッチングソフトウェア市場規模は2030年までに3億9,613万米ドルに達する見込みです。

2025～2030年のCAGRは13.45%で拡大する見込みです。進行中の臨床検査数の大幅な増加が市場を牽引するとみられます。また、臨床検査に対応する臨床検査マッチングソフトウェアの採用が増加していることや、医療セグメントにおける仮想検査や自動化の需要が増加していることも、市場成長に寄与する主要因の1つです。マッチングソフトウェアは、患者中心のアプローチで効果的かつ迅速な患者マッチングに役立ちます。

臨床検査では、患者のリクルートやマッチングに時間がかかり、適切なマッチングを見つけることが困難な場合があります。資格のある回答候補者のスクリーニングや所在確認、治験のあらゆる要素の検討、認知度の確認、参加へのインフォームドコンセントの取得などは、患者募集の際に考慮される要素です。資格要件に従って個人を採用することは極めて重要であり、それゆえ、特にCOVID-19のシナリオでは、トライアルマッチング技術が有用であることが証明されています。

このソフトウェアは、適切なマッチングを見つけるだけでなく、研究開発関連コストの節約にも役立ち、人手を介さずに円滑な運営を可能にしています。ソフトウェアプロバイダは、市場での地位を強化するために新しい革新的な技術を導入しています。例えば、2022年2月、CTMAはリウマチ領域におけるCT-SCOUT技術の提供を拡大しました。

臨床検査マッチングソフトウェア市場レポートハイライト

• 展開モード別では、ウェブとクラウドベースのセグメントが2024年の収益で市場を独占し、予測期間中に最も速いCAGRを記録すると予想されます。クラウドコンピューティングモデルは、メンテナンスや維持費が不要で、顧客は利用したサービスに対してのみ料金を支払えばよいです。一方、オンプレミスの導入には、社内のインフラ、社内のITサポート、運転資金、高い統合コストがかかります。そのため、ウェブやクラウドベースのモデルが好まれます。
• 最終用途別では、製薬企業とバイオテクノロジー企業が2024年に最大の収益シェアを獲得しました。
• 契約研究機関（CRO）セグメントは、予測期間中に最も速いCAGRを記録すると予想されます。CROは、臨床検査に必要な専門的支援、専門知識、実施経験を迅速に提供するため、スポンサーが専任の人材を雇用する必要はないです。CROのサービスは費用対効果、時間対効果が高いため、アウトソーシング先として好まれています。
• 同地域の製薬、バイオテクノロジー、医療関連企業による臨床検査マッチングソフトウェアの採用が増加していることから、2024年には北米が企業収益で市場をリードすることになります。
• アジア太平洋は、患者/候補者の容易なリクルートをサポートする大規模な患者プールが利用可能であるため、予測期間中に最も速い成長率を記録すると予想されます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 臨床検査マッチングソフトウェア市場の変数、動向、範囲

• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
  • 市場機会分析
• 臨床検査マッチングソフトウェア市場分析ツール
  • 産業分析-ポーターのファイブフォース分析
  • PESTEL分析
  • 新興技術
  • 使用事例と洞察
  • COVID-19の影響分析

第4章 臨床検査マッチングソフトウェア市場：展開モード、推定・動向分析

• 展開モード市場シェア、2024年と2030年
• セグメントダッシュボード
• 展開モード別世界の臨床検査マッチングソフトウェア市場展望
• ウェブとクラウドベース
• オンプレミス

第5章 臨床検査マッチングソフトウェア市場：最終用途別、推定・動向分析

• 最終用途市場シェア、2024年と2030年
• セグメントダッシュボード
• 最終用途別臨床検査マッチングソフトウェア市場展望
• 製薬・バイオテクノロジー企業
• CRO
• 医療機器企業

第6章 臨床検査マッチングソフトウェア市場：地域推定・動向分析、展開モード別、最終用途別

• 地域別市場シェア分析、2024年と2030年
• 地域別市場ダッシュボード
• 世界地域市場のスナップショット
• 市場規模と予測動向分析、2018～2030年
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• 主要企業の市場シェア/ポジション分析、2024年
• 企業プロファイル
  • IBM
  • Antidote Technologies, Inc.
  • RealTime Software Solutions, LLC
  • Optimapharm.
  • Advarra
  • BSI Business Systems Integration AG
  • Clario
  • HealthMatch
  • Microsoft
  • Deep6.ai
  • Inspirata, Inc.
  • Mendel Health Inc.
  • MatchTrial
  • Curewiki
  • Inteliquet（IQVIA）
  • Tempus Labs

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 North America clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
• Table 4 North America clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 5 U.S. clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
• Table 6 U.S. clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 7 Canada clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
• Table 8 Canada clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 9 Mexico clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
• Table 10 Mexico clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 11 Europe clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
• Table 12 Europe clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 13 UK clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
• Table 14 UK clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 15 Germany clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
• Table 16 Germany clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 17 France clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
• Table 18 France clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 19 Italy clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
• Table 20 Italy clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 21 Spain clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
• Table 22 Spain clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 23 Sweden clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
• Table 24 Sweden clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 25 Denmark clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
• Table 26 Denmark clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 27 Norway clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
• Table 28 Norway clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 29 Asia Pacific clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
• Table 30 Asia Pacific clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 31 Japan clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
• Table 32 Japan clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 33 China clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
• Table 34 China clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 35 India clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
• Table 36 India clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 37 Australia clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
• Table 38 Australia clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 39 South Korea clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
• Table 40 South Korea clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 41 Thailand clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
• Table 42 Thailand clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 43 Latin America clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
• Table 44 Latin America clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 45 Brazil clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
• Table 46 Brazil clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 47 Argentina clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
• Table 48 Argentina clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 49 MEA clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
• Table 50 MEA clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 51 South Africa clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
• Table 52 South Africa clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 53 Saudi Arabia clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
• Table 54 Saudi Arabia clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 55 UAE clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
• Table 56 UAE clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 57 Kuwait clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
• Table 58 Kuwait clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Clinical Trials Matching Software Market Segmentation
• Fig. 2 Information Procurement
• Fig. 3 Data Analysis Models
• Fig. 4 Market Formulation and Validation
• Fig. 5 Data Validating & Publishing
• Fig. 6 Market Snapshot
• Fig. 7 Segment Snapshot (1/2)
• Fig. 8 Segment Snapshot (2/2)
• Fig. 9 Competitive Landscape Snapshot
• Fig. 10 Clinical Trials Matching Software- Market Size and Growth Prospects (USD Million)
• Fig. 11 Clinical Trials Matching Software Market: Industry Value Chain Analysis
• Fig. 12 Clinical Trials Matching Software Market: Market Dynamics
• Fig. 13 Clinical Trials Matching Software Market: PORTER's Analysis
• Fig. 14 Clinical Trials Matching Software Market: PESTEL Analysis
• Fig. 15 Clinical Trials Matching Software Market: Deployment Mode Movement Analysis, 2018 - 2030 (USD Million)
• Fig. 16 Clinical Trials Matching Software Market Share Analysis by Deployment Mode, 2024 & 2030
• Fig. 17 Web & Cloud-based Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
• Fig. 18 On-premises Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
• Fig. 19 Clinical Trials Matching Software Market: End Use Movement Analysis, 2018 - 2030 (USD Million)
• Fig. 20 Clinical Trials Matching Software Market Share Analysis by End Use, 2024 & 2030
• Fig. 21 Pharmaceutical & Biotechnology Companies Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
• Fig. 22 CROs Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
• Fig. 23 Medical Device Companiess Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
• Fig. 24 Clinical Trials Matching Software Market Revenue, by Region, 2024 & 2030 (USD Million)
• Fig. 25 Regional Marketplace: Key Takeaways
• Fig. 26 North America Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 27 U.S. Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 28 Canada Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 29 Mexico Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 30 Europe Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 31 UK Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030) (USD Million)
• Fig. 32 Germany Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 33 France Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Italy Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Spain Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Sweden Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 37 Denmark Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Norway Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Asia Pacific Clinical Trials Matching Software Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 40 Japan Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 41 China Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 42 India Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 43 Australia Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Thailand Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 45 Latin America Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Brazil Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 47 Argentina Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 48 MEA Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Saudi Arabia Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 50 UAE Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 51 South Africa Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Kuwait Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 53 Key Company Categorization
• Fig. 54 Company Market Positioning
• Fig. 55 Key Company Market Share Analysis, 2024
• Fig. 56 Strategic Framework

Clinical Trials Matching Software Market Growth & Trends:

The global clinical trials matching software market size is expected to reach USD 396.13 million by 2030, based on a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 13.45% from 2025 to 2030. The significant increase in the number of ongoing clinical trials is likely to drive the market. In addition, the growing adoption of the clinical trial matching software catering to the clinical trials, along with the increased demand for virtual trials and automation in the healthcare sector are some of the key factors contributing to the market growth. The matching software help in effective and fast patient matching with patient-centric approaches.

In clinical trials, patient recruitment or matching can be time-consuming, and finding the right match can be a hurdle. Screening or locating prospective respondents who are qualified, considering all elements of the trials, verifying awareness, and getting informed consent to participate are the factors taken into consideration while recruiting patients. Enlisting the individuals in accordance with the qualifying requirements is crucial, hence the trial matching technology has been proved to be useful, especially in the COVID-19 scenario.

The software helps not only to find the right match but also saves the R&D-related costs, enabling smoother operations without human intervention. The software providers are introducing new innovative techniques to strengthen their market position. For instance, in February 2022, the CTMA expanded CT-SCOUT technology offering in rheumatology.

Clinical Trials Matching Software Market Report Highlights:

• Based on deployment mode, the web and cloud based segment dominated the market in terms of revenue in 2024 and it is expected to register the fastest CAGR during the forecast period. The cloud computing models operate with no maintenance or upkeep charges and customers only have to pay for the services that are used. On the other hand, on-premises deployment involves in-house infrastructure, in-house IT support, working capital, and higher integration costs. Hence, web and cloud based models are preferred
• Based on end use, pharmaceuticals and biotechnology companies captured the largest revenue share in 2024 owing to the higher adoption of software during ongoing clinical studies for cost-saving in the R&D activities
• Contract Research Organizations (CRO) segment is expected to register the fastest CAGR over the forecast period. CROs provide the professional assistance, expertise, and execution experience required for clinical trials quickly, without the need for the sponsor to engage such people full-time. CROs are preferred for outsourcing as their services are cost and time-effective
• In 2024, North America led the market in terms of revenue owing to the rising adoption of the clinical trial matching software by the pharma, biotech, and medical companies in the region
• Asia Pacific is anticipated to register the fastest growth rate over the forecast period due to the availability of a large patient pool supporting easy recruitment of patients/candidates

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Deployment mode
  • 1.1.2. End Use
  • 1.1.3. Regional scope
  • 1.1.4. Estimates and forecast timeline.
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
  • 1.6.2. Approach 1: Commodity flow approach
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Deployment mode outlook
  • 2.2.2. End use
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Clinical Trials Matching Software Market Variables, Trends & Scope

• 3.1. Market Dynamics
  • 3.1.1. Market Driver Analysis
    • 3.1.1.1. Growing Complexity of Clinical Trials
    • 3.1.1.2. Increasing Demand for Precision Medicine & Personalized Trials
    • 3.1.1.3. Regulatory Push for Enhanced Patient Enrollment Efficiency
    • 3.1.1.4. Rising Investments in Digital Health & Clinical Research Technologies
    • 3.1.1.5. Expanding Clinical Trial Pipelines & Decentralized Trials
    • 3.1.1.6. Partnerships Between Pharma Companies & Tech Firms for Advanced Solutions
  • 3.1.2. Market Restraint Analysis
    • 3.1.2.1. High Implementation and Maintenance Costs
    • 3.1.2.2. Data Privacy and Security Concerns
  • 3.1.3. Market Opportunities Analysis
• 3.2. Clinical Trials Matching Software Market Analysis Tools
  • 3.2.1. Industry Analysis - Porter's
    • 3.2.1.1. Supplier power
    • 3.2.1.2. Buyer power
    • 3.2.1.3. Substitution threat
    • 3.2.1.4. Threat of new entrant
    • 3.2.1.5. Competitive rivalry
  • 3.2.2. PESTEL Analysis
    • 3.2.2.1. Political landscape
    • 3.2.2.2. Economic landscape
    • 3.2.2.3. Social landscape
    • 3.2.2.4. Technological landscape
    • 3.2.2.5. Environmental landscape
    • 3.2.2.6. Legal landscape
  • 3.2.3. Emerging Technologies
  • 3.2.4. Case Studies & Insights
  • 3.2.5. COVID-19 Impact Analysis

Chapter 4. Clinical Trials Matching Software Market: Deployment Mode Estimates & Trend Analysis

• 4.1. Deployment Mode Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Clinical Trials Matching Software Market by Deployment Mode Outlook
• 4.4. Web & Cloud-based
  • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.5. On-Premises
  • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Clinical Trials Matching Software Market: End Use Estimates & Trend Analysis

• 5.1. End Use Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Clinical Trials Matching Software Market by End Use Outlook
• 5.4. Pharmaceutical & Biotechnology Companies
  • 5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.5. CROs
  • 5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.6. Medical Device Companies
  • 5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Clinical Trials Matching Software Market: Regional Estimates & Trend Analysis, By Deployment Mode and By End Use

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Global Regional Market Snapshot
• 6.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 6.5. North America
  • 6.5.1. U.S.
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Canada
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. Mexico
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Europe
  • 6.6.1. UK
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Germany
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.3. France
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.4. Italy
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.5. Spain
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.6. Norway
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.7. Sweden
    • 6.6.7.1. Key country dynamics
    • 6.6.7.2. Regulatory framework
    • 6.6.7.3. Competitive scenario
    • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.8. Denmark
    • 6.6.8.1. Key country dynamics
    • 6.6.8.2. Regulatory framework
    • 6.6.8.3. Competitive scenario
    • 6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Asia Pacific
  • 6.7.1. Japan
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. China
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. India
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Australia
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.5. South Korea
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory framework
    • 6.7.5.3. Competitive scenario
    • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.6. Thailand
    • 6.7.6.1. Key country dynamics
    • 6.7.6.2. Regulatory framework
    • 6.7.6.3. Competitive scenario
    • 6.7.6.4. Singapore market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Latin America
  • 6.8.1. Brazil
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework
    • 6.8.1.3. Competitive scenario
    • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.2. Argentina
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. MEA
  • 6.9.1. South Africa
    • 6.9.1.1. Key country dynamics
    • 6.9.1.2. Regulatory framework
    • 6.9.1.3. Competitive scenario
    • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.2. Saudi Arabia
    • 6.9.2.1. Key country dynamics
    • 6.9.2.2. Regulatory framework
    • 6.9.2.3. Competitive scenario
    • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.3. UAE
    • 6.9.3.1. Key country dynamics
    • 6.9.3.2. Regulatory framework
    • 6.9.3.3. Competitive scenario
    • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.4. Kuwait
    • 6.9.4.1. Key country dynamics
    • 6.9.4.2. Regulatory framework
    • 6.9.4.3. Competitive scenario
    • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Key company market share/position analysis, 2024
• 7.4. Company Profiles
  • 7.4.1. IBM
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Technology Type benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Antidote Technologies, Inc.
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Technology Type benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. RealTime Software Solutions, LLC
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Technology Type benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Optimapharm.
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Technology Type benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. Advarra
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Technology Type benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. BSI Business Systems Integration AG
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Technology Type benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. Clario
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Technology Type benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. HealthMatch
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Technology Type benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. Microsoft
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Technology Type benchmarking
    • 7.4.9.4. Strategic initiatives
  • 7.4.10. Deep6.ai
    • 7.4.10.1. Company overview
    • 7.4.10.2. Financial performance
    • 7.4.10.3. Technology Type benchmarking
    • 7.4.10.4. Strategic initiatives
  • 7.4.11. Inspirata, Inc.
    • 7.4.11.1. Company overview
    • 7.4.11.2. Financial performance
    • 7.4.11.3. Technology Type benchmarking
    • 7.4.11.4. Strategic initiatives
  • 7.4.12. Mendel Health Inc.
    • 7.4.12.1. Company overview
    • 7.4.12.2. Financial performance
    • 7.4.12.3. Technology Type benchmarking
    • 7.4.12.4. Strategic initiatives
  • 7.4.13. MatchTrial
    • 7.4.13.1. Company overview
    • 7.4.13.2. Financial performance
    • 7.4.13.3. Technology Type benchmarking
    • 7.4.13.4. Strategic initiatives
  • 7.4.14. Curewiki
    • 7.4.14.1. Company overview
    • 7.4.14.2. Financial performance
    • 7.4.14.3. Technology Type benchmarking
    • 7.4.14.4. Strategic initiatives
  • 7.4.15. Inteliquet (IQVIA)
    • 7.4.15.1. Company overview
    • 7.4.15.2. Financial performance
    • 7.4.15.3. Technology Type benchmarking
    • 7.4.15.4. Strategic initiatives
  • 7.4.16. Tempus Labs
    • 7.4.16.1. Company overview
    • 7.4.16.2. Financial performance
    • 7.4.16.3. Technology Type benchmarking
    • 7.4.16.4. Strategic initiatives